A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Completed

Conditions studied: Squamous Non-small Cell Lung Cancer

In brief

This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second line (2L) therapy.

Key facts

Study ID

NCT04552535

Run by

Boehringer Ingelheim

People needed

200

Starts

2020-05-08

Expected to finish

2020-05-18

Last updated by the study team

2022-01-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of squamous or mixed histology non-small cell lung cancer
• Treated with pembrolizumab in combination with platinum-based chemotherapy as initial therapy for advanced or metastatic disease (stage IIIB or IV)
• First cycle of pembrolizumab received after 06/01/2018
• Permanently discontinued 1L pembrolizumab treatment
• Initiated second-line treatment at least 3 months prior to the date of data collection, with either :
• Afatinib
• Any chemotherapy
• Age ≥ 18 years

You may not qualify if…

• Received pembrolizumab in combination with platinum-based chemotherapy as part of an interventional clinical trial

Where it is running

• Cardinal Health Specialty Solutions — Dublin, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.